Sanacora 2014 (a).

Study characteristics
Methods	Double‐blind randomised controlled trial
Participants	Diagnosis: DSM‐IV major depressive disorder; at least two adequate lifetime antidepressant trials that failed; HRSD‐17 score ≥ 20 N: 34 Age: lanicemine group M = 47.6 (SE = 3.0); placebo group M = 43.9 (SE = 3.0) Sex: lanicemine group 56% female; placebo group 61% female Baseline depression severity: lanicemine group HAM‐D = 25.9 (SD = 1.1); placebo group MADRS = 25.4 (SD = 0.8)
Interventions	1 single IV infusion Lanicemine (AZD6765) (N = 16) 100 mg infused over 60 minutes Placebo (N = 18) 0.9% saline infused over 60 minutes Concomitant treatment: Unclear
Outcomes	MADRS VAS BPRS CogState Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: ''double‐blind randomized study'' no further details given
Allocation concealment (selection bias)	Unclear risk	Quote: ''double‐blind randomized study'' no further details given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: ''double‐blind'' no further details given
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: ''double‐blind'' no further details given
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Dropouts not reported
Selective reporting (reporting bias)	Unclear risk	Protocol unavailable. Data reported matches methods
Other bias	Low risk	No other potential sources of bias identified